The prospective, multicenter, randomized phase 2 ZZ-FIRST clinical trial, led by the Vall d'Hebron Institute of Oncology's ...

A prospective study demonstrates that surgical and medical androgen deprivation therapies deliver comparable short-term ...

A case report in BMC Urology describes isolated omental metastasis from high-risk prostate adenocarcinoma, highlighting ...

A new study led by researchers at the UCLA Health Jonsson Comprehensive Cancer Center has found that many cases of high-risk nonmetastatic hormone-sensitive prostate cancer may be more advanced than ...

In a recent Yale-led clinical trial, a new type of prostate cancer drug showed promising results in reducing tumor activity ...

Three phase 3 prostate cancer results from ESMO 2026 cover long-term survival with abiraterone in metastatic disease, Erleada before and after surgery, and an update on Truqap for PTEN-deficient ...

For men with genitourinary malignancies, such as prostate cancer, examining the external genital area is essential. While this may seem routine, it remains a crucial recommendation, as illustrated by ...

ORION CORPORATION PRESS RELEASE 24 OCTOBER 2026 at 9.35 EEST Darolutamide plus ADT and radiation therapy reduces risk of metastasis or ...

Explore integrative therapies for metastatic prostate cancer, including nutrition, acupuncture, supplements, exercise, and ...

First-of-its-kind dual-antigen-targeted bispecific regimen of pasritamig and JNJ-9401 directed at two prostate cancer proteins, KLK2 and PSMA, using complementary signals to activate T cells against ...